2-(4-ethoxybenzyl)-N,N-diethyl-1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide

ID: ALA4082936

Chembl Id: CHEMBL4082936

PubChem CID: 22181436

Max Phase: Preclinical

Molecular Formula: C28H38N4O2

Molecular Weight: 462.64

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCOc1ccc(Cc2nc3cc(C(=O)N(CC)CC)ccc3n2CCN2CCCCC2)cc1

Standard InChI:  InChI=1S/C28H38N4O2/c1-4-31(5-2)28(33)23-12-15-26-25(21-23)29-27(20-22-10-13-24(14-11-22)34-6-3)32(26)19-18-30-16-8-7-9-17-30/h10-15,21H,4-9,16-20H2,1-3H3

Standard InChI Key:  JRJWAARCOBEVOL-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4082936

   2-(4-Ethoxybenzyl)-N,N-diethyl-1-[2-(1-piperidinyl)ethyl]-1H-benzimidazole-5-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 462.64

Molecular Weight (Monoisotopic): 462.2995

AlogP: 4.99

#Rotatable Bonds: 10

Polar Surface Area: 50.60

Molecular Species: BASE

HBA: 5

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 9.11

CX LogP: 4.52

CX LogD: 2.81

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.43

Np Likeness Score: -1.80

References

1. Dolles D, Hoffmann M, Gunesch S, Marinelli O, Möller J, Santoni G, Chatonnet A, Lohse MJ, Wittmann HJ, Strasser A, Nabissi M, Maurice T, Decker M..  (2018)  Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles.,  61  (4): [PMID:29400965] [10.1021/acs.jmedchem.7b01760]

2. Mangiatordi GF, Intranuovo F, Delre P, Abatematteo FS, Abate C, Niso M, Creanza TM, Ancona N, Stefanachi A, Contino M..  (2020)  Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration.,  63  (23.0): [PMID:33094613] [10.1021/acs.jmedchem.0c01357]

Source

Source(1):

• Scientific Literature